Bevacizumab versus ranibizumab in the treatment of macular edema due to retinal vein occlusion: 6-month results of the CRAVE study

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 46, Issue 8, 2015, Pages 844-850

  Rajagopal, Rithwick ^a   Shah, Gaurav K ^b   Blinder, Kevin J ^b   Altaweel, Michael ^c   Eliott, Dean ^d   Wee, Raymond ^e   Cooper, Blake ^f   Walia, Harpreet ^b   Smith, Bradley ^b   Joseph, Daniel P ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b Retina Institute   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^e Retina Center of Hawaii   (United States)

^f PA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; STEROID; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMIRETINAL VEIN OCCLUSION; HUMAN; INJECTION SITE PAIN; MACULAR EDEMA; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA VEIN OCCLUSION; TREATMENT RESPONSE; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; RETINAL VEIN OCCLUSION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANIBIZUMAB; RETINA; RETINAL VEIN OCCLUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84942515993     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20150909-09     Document Type: Article

References (15)

1. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
2. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119:1024-1032.
3. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 117(6):1124-1133 e1.
4. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122:538-544.
5. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 117:1102-1112 e1.
6. Epstein DL, Algvere PV, von Wendt G, et al. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, doublemasked clinical study. Ophthalmology. 2012;119:1184-1189.
7. Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-1908.
8. Berg K, Pedersen TR, Sandvik L, et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122:146-152.
9. IVAN Study Investigators, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399-1411.
10. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: Results from the GEFAL noninferiority randomized trial. Ophthalmology. 2013;120:2300-2309.
11. Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97:266-271.
12. The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;26;372:1193-1203.
13. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859-870.
14. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg. 1997;13:388-391.
15. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155:429-437 e7.